BioCentury | Apr 15, 2013
Company News

Innovir management update

...diseases/AIDS Hired: Francis O'Connell as CFO; he retains his position as VP of finance at VIMRx...
BioCentury | Dec 8, 2008
Company News

VimRx, Columbia University deal

...through the company's new VIMRx Genomics Inc. subsidiary (New York, N.Y.). During the five-year collaboration, VimRx...
...is used for drug target identification and validation. VMRX initially will own 90 percent of VimRx...
...partnerships with pharmaceutical and/or diagnostic companies and intends to solicit equity investments in VimRx Genomics. VimRx...
BioCentury | Dec 8, 2008
Company News

VimRx management update

...Wilmington, Del. Business: Infectious diseases/AIDS Hired: Richard Kouri, Ph.D., as president and CEO of VMRX's Vimrx...
BioCentury | Dec 8, 2008
Company News

VimRx management update

VimRx Pharmaceuticals Inc. (VMRX), Wilmington, Del. Business: Gene/Cell therapy, Infectious diseases/AIDS Hired: L. William MacIntosh as SVP of business development and finance and CFO; formerly consultant to SmithKline Beecham Pharmaceuticals WIR Staff Infectious...
BioCentury | Dec 8, 2008
Clinical News

VimRx preclinical data

...heparin. Data were reported at the meeting of the American Heart Association in Orlando, Fla. VimRx...
BioCentury | Dec 8, 2008
Company News

VimRx, Columbia University deal

...VMRX, which will call the compound VM201, hopes to file an IND early next year. VimRx...
BioCentury | Dec 8, 2008
Company News

VimRx, Baxter deal

...$21 million in milestones to Baxter related to regulatory approval (see Noteworthy, BioCentury Part I). VimRx...
BioCentury | Nov 4, 2002
Finance

Restructuring watch

...NRGN) 10% to 216 Hopes to stretch cash into early 2005 $89.7 6.5 6/30 10/17 Nexell...
BioCentury | Oct 21, 2002
Company News

Nexell, Baxter Healthcare Corp. gene/cell therapy news

...and its affiliates, the sole preferred stockholders, will receive all the remaining assets, NEXL said. Nexell Therapeutics Inc....
BioCentury | Sep 30, 2002
Company News

Xoma management update

...Autoimmune/Inflammation Hired: Michel Bergh as VP of business development, formerly VP of business development at Nexell Therapeutics Inc....
Items per page:
1 - 10 of 141
BioCentury | Apr 15, 2013
Company News

Innovir management update

...diseases/AIDS Hired: Francis O'Connell as CFO; he retains his position as VP of finance at VIMRx...
BioCentury | Dec 8, 2008
Company News

VimRx, Columbia University deal

...through the company's new VIMRx Genomics Inc. subsidiary (New York, N.Y.). During the five-year collaboration, VimRx...
...is used for drug target identification and validation. VMRX initially will own 90 percent of VimRx...
...partnerships with pharmaceutical and/or diagnostic companies and intends to solicit equity investments in VimRx Genomics. VimRx...
BioCentury | Dec 8, 2008
Company News

VimRx management update

...Wilmington, Del. Business: Infectious diseases/AIDS Hired: Richard Kouri, Ph.D., as president and CEO of VMRX's Vimrx...
BioCentury | Dec 8, 2008
Company News

VimRx management update

VimRx Pharmaceuticals Inc. (VMRX), Wilmington, Del. Business: Gene/Cell therapy, Infectious diseases/AIDS Hired: L. William MacIntosh as SVP of business development and finance and CFO; formerly consultant to SmithKline Beecham Pharmaceuticals WIR Staff Infectious...
BioCentury | Dec 8, 2008
Clinical News

VimRx preclinical data

...heparin. Data were reported at the meeting of the American Heart Association in Orlando, Fla. VimRx...
BioCentury | Dec 8, 2008
Company News

VimRx, Columbia University deal

...VMRX, which will call the compound VM201, hopes to file an IND early next year. VimRx...
BioCentury | Dec 8, 2008
Company News

VimRx, Baxter deal

...$21 million in milestones to Baxter related to regulatory approval (see Noteworthy, BioCentury Part I). VimRx...
BioCentury | Nov 4, 2002
Finance

Restructuring watch

...NRGN) 10% to 216 Hopes to stretch cash into early 2005 $89.7 6.5 6/30 10/17 Nexell...
BioCentury | Oct 21, 2002
Company News

Nexell, Baxter Healthcare Corp. gene/cell therapy news

...and its affiliates, the sole preferred stockholders, will receive all the remaining assets, NEXL said. Nexell Therapeutics Inc....
BioCentury | Sep 30, 2002
Company News

Xoma management update

...Autoimmune/Inflammation Hired: Michel Bergh as VP of business development, formerly VP of business development at Nexell Therapeutics Inc....
Items per page:
1 - 10 of 141